Susquehanna International Group
LCTX icon

Susquehanna International Group’s Lineage Cell Therapeutics LCTX Stock Holding History

Susquehanna International Group’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$126K Buy
79,800
+28,700
+56% +$48.4K ﹤0.01% 12177
2025
Q4 		$85.3K Sell
51,100
-58,200
-53% -$101K ﹤0.01% 11540
2025
Q3 		$185K Buy
109,300
+41,000
+60% +$48.5K ﹤0.01% 11075
2025
Q2 		$62.2K Buy
+68,300
New +$40.5K ﹤0.01% 12046
2025
Q1 		– Sell
-17,100
Closed -$8.55K – 13032
2024
Q4 		$8.55K Buy
+17,100
New +$12.6K ﹤0.01% 11992
2023
Q4 		– Sell
-14,500
Closed -$17.1K – 12877
2023
Q3 		$17.1K Buy
+14,500
New +$19.7K ﹤0.01% 11639
2022
Q4 		– Sell
-81,200
Closed -$92K – 13110
2022
Q3 		$92K Sell
81,200
-80,500
-50% -$118K ﹤0.01% 11769
2022
Q2 		$255K Buy
161,700
+11,400
+8% +$15K ﹤0.01% 10001
2022
Q1 		$231K Sell
150,300
-203,600
-58% -$316K ﹤0.01% 10893
2021
Q4 		$867K Sell
353,900
-57,700
-14% -$135K ﹤0.01% 7667
2021
Q3 		$1.04M Buy
411,600
+278,000
+208% +$713K ﹤0.01% 7464
2021
Q2 		$381K Buy
133,600
+118,200
+768% +$306K ﹤0.01% 10249
2021
Q1 		$36K Sell
15,400
-428,900
-97% -$1.03M ﹤0.01% 12089
2020
Q4 		$782K Buy
444,300
+397,500
+849% +$556K ﹤0.01% 7269
2020
Q3 		$44K Buy
46,800
+6,400
+16% +$5.65K ﹤0.01% 10232
2020
Q2 		$35K Sell
40,400
-26,000
-39% -$22.9K ﹤0.01% 9837
2020
Q1 		$55K Buy
+66,400
New +$66.1K ﹤0.01% 9645
2019
Q4 		– Sell
-18,800
Closed -$18K – 10214
2019
Q3 		$18K Buy
18,800
+3,000
+19% +$3.11K ﹤0.01% 9963
2019
Q2 		$17K Sell
15,800
-11,200
-41% -$12.9K ﹤0.01% 10026
2019
Q1 		$35K Buy
27,000
+7,600
+39% +$9.45K ﹤0.01% 8532
2018
Q4 		$18K Buy
+19,400
New +$29.7K ﹤0.01% 8692
2017
Q4 		– Sell
-55,550
Closed -$138K – 9609
2017
Q3 		$138K Buy
+55,550
New +$138K ﹤0.01% 8240
2016
Q1 		– Sell
-17,346
Closed -$57K – 9377
2015
Q4 		$57K Buy
+17,346
New +$51.8K ﹤0.01% 9071
2015
Q3 		– Sell
-187,463
Closed -$549K – 9907
2015
Q2 		$549K Buy
187,463
+118,078
+170% +$458K ﹤0.01% 7445
2015
Q1 		$278K Buy
69,385
+23,542
+51% +$81.4K ﹤0.01% 8108
2014
Q4 		$138K Buy
45,843
+25,151
+122% +$68K ﹤0.01% 9056
2014
Q3 		$52K Buy
+20,692
New +$49.8K ﹤0.01% 9214

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RA
Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group's LCTX Position: Q1 2026 in Review

Susquehanna International Group increased its Lineage Cell Therapeutics (LCTX) stake by 85% in Q1 2026, buying an estimated $1.01M and bringing the position to 1,304,685 shares worth $2.06M. The position accounts for ﹤0.01% of the portfolio, ranked #6121.

Susquehanna International Group first reported a position in LCTX in Q2 2013 and has held it in 39 quarters since. The position peaked at $2.35M in Q1 2021. 130 funds tracked by Wall St. Rank hold LCTX as of Q1 2026.

  • Susquehanna International Group held 1,304,685 shares of Lineage Cell Therapeutics worth $2.06M as of Q1 2026.
  • Susquehanna International Group bought 598,270 Lineage Cell Therapeutics shares in Q1 2026, an estimated $1.01M.
  • Lineage Cell Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #6121 holding.
  • Susquehanna International Group first reported a position in Lineage Cell Therapeutics in Q2 2013 and has held it in 39 quarters since.
  • Susquehanna International Group's Lineage Cell Therapeutics position peaked at $2.35M in Q1 2021.
  • 130 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.